Motricity, Inc. (NASDAQ: MOTR) is a leading mobile data solutions provider exclusively focused on the rapidly growing mobile Internet market. It serves some of the world's largest mobile carriers, simplifying the mobile Internet and creating a personalized mobile experience for subscribers. Motricity helps companies leverage the power of mobility to make direct, personalized connections with their customers.

Motricity, Inc. raised $60.0 million in its initial public offering at $10 per share. Needham acted as a Co-Manager on the transaction. The net proceeds from the sale of the shares will be used by Motricity, Inc. primarily to fund investments in, and acquisitions of, competitive and complementary businesses, products or technologies, and other general corporate purposes.

BroadSoft, Inc. (NASDAQ: BSFT) is the leading global provider of software that enables fixed-line, mobile and cable service providers to deliver voice and multimedia services over their IP-based networks. The Company's software, BroadWorks®, enables its service provider customers to provide enterprises and consumers with a range of cloud-based, or hosted, IP multimedia communications, such as hosted IP private branch exchanges, video calling, unified communications, collaboration and converged mobile and fixed-line services.

BroadSoft, Inc. raised $67.5 million in its initial public offering at $9 per share. Needham acted as a Co-Manager on the transaction. The net proceeds from the sale of the shares will be used by BroadSoft, Inc. primarily to fund redemption and cancellation of preferred stock, repay existing debt, working capital, and other general corporate purposes.

MELA Sciences, Inc. (NASDAQ: MELA) is a medical technology company focused on developing MelaFind®, a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. MELA Sciences designed MelaFind® to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind® acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma. The MelaFind Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009 and is currently under review at the FDA. MELA Sciences cannot predict either the timing of the FDA's decision on the PMA application or the outcome. FDA approval is required prior to marketing MelaFind® in the United States. For more information on MELA Sciences, visit www.melasciences.com.

MELA Sciences, Inc. raised $16.5 million in a follow-on offering at $7.50 per share. Needham & Company acted as joint bookrunner on the transaction. The net proceeds from this transaction will be used by MELA Sciences, Inc. to fund the pursuit of its pre-market approval application (PMA) for MelaFind®, the continued development and, if and when approved by the U.S. Food and Drug Administration (FDA), the commercialization of MelaFind®, and for general corporate purposes, including working capital.

Sound Design Technologies, Ltd., an affiliate of Global Equity Capital, LLC is a leading designer and manufacturer of ultra-low-power semiconductor solutions for hearing aids and portable, battery-powered DSP applications, and a leading provider of advanced high density interconnect technologies used in custom miniaturized packages. Based in Burlington, Ontario, Canada, SDT has a 37-year history of innovation in developing miniaturized audio processors. The hearing instrument products and manufacturing operations of Gennum Corporation were acquired in 2007 to form SDT.

Needham & Company acted as financial advisor to Sound Design Technologies, Ltd. (STD) in its sale to ON Semiconductor Corporation (NASDAQ: ONNN) in an all cash transaction valued at approximately $32 million. This acquisition solidifies ON Semiconductor as a leading supplier of ultra-low-power digital signal processing (DSP) technology for hearing aids and audio processing applications. Matching SDT’s cutting-edge technology with ON Semiconductor’s worldwide presence and industry expertise is a natural next step in the evolution of the business, also benefiting SDT customers building sophisticated hearing products. ON Semiconductor Corporation is a premier supplier of high performance, energy efficient, silicon solutions for green electronics. Its broad portfolio of power and signal management, logic, discrete and custom devices helps customers efficiently solve their design challenges in automotive, communications, computing, consumer, industrial, LED lighting, medical, military/aerospace and power applications.

Heritage-Crystal Clean, Inc. (NASDAQ: HCCI) provides parts cleaning and hazardous and non-hazardous waste services to small and mid-sized customers in both the manufacturing and automotive service sectors. Their service programs include parts cleaning, containerized waste management, used oil collection, and vacuum truck services. These services help our customers manage their used chemicals and liquid and solid wastes, while also helping to minimize their regulatory burdens. Heritage-Crystal Clean’s customers include businesses involved in vehicle maintenance operations, such as car dealerships, automotive repair shops, and trucking firms, as well as small manufacturers, such as metal product fabricators and printers. The company is headquartered in Elgin, Illinois, and operates through 62 branches serving over 41,000 customer locations.

Heritage-Crystal Clean, Inc. raised $27.6 million in a follow-on offering at $8 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 450,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Heritage-Crystal Clean to fund a portion of the construction costs for the used oil re-refinery that it plans to build in Indiana.

Bottomline Technologies (NASDAQ: EPAY) is a leading provider of collaborative payment, invoice and document automation solutions to corporations, financial institutions and banks around the world. The company’s solutions are used to streamline, automate and manage processes involving payments, invoicing, global cash management, supply chain finance and transactional documents. Organizations trust these solutions to meet their needs for cost reduction, competitive differentiation and optimization of working capital. Headquartered in the United States, Bottomline also maintains offices in Europe and Asia-Pacific.

Bottomline Technologies raised $66.0 million in a follow-on offering at $14.50 per share. Needham & Company acted as sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 345,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Bottomline Technologies for general corporate purposes including acquisitions, working capital and capital expenditures.

ReachLocal, Inc.'s (NASDAQ: RLOC) mission is to help small- and medium-sized businesses acquire, maintain and retain customers via the Internet. ReachLocal offers a comprehensive suite of online marketing and reporting solutions, including search engine marketing, display advertising, remarketing and online marketing analytics, each targeted to the small- and medium-sized business market. ReachLocal delivers these solutions to small- and medium-sized businesses through a combination of its proprietary technology platform and its direct, "feet-on-the-street" sales force of Internet Marketing Consultants and select third party agencies and resellers. ReachLocal is headquartered in Woodland Hills, CA, with offices throughout North America and in Australia and the United Kingdom.

ReachLocal, Inc. raised $62.3 million in its initial public offering at $13 per share. Needham acted as a Co-Manager on the transaction.  The Company’s underwriters fully exercised their option to purchase an additional 625,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by ReachLocal, Inc. primarily for working capital and general corporate purposes. The Company will also use a portion of net proceeds of this offering to fulfill a deferred payment obligation of $6.1 million in connection with the acquisition in September 2009 of the approximately 53% of the Australian operations that the Company did not already own. The Company may use a portion of the net proceeds to acquire or invest in rights to complementary technologies, products, services or businesses.

Advanced Energy Industries, Inc. (NASDAQ: AEIS) is a global leader in innovative power and control technologies for high-growth, thin-film manufacturing and solar-power generation. Specifically, Advanced Energy targets solar grid-tie inverters, solar cells, semiconductors, flat panel displays, data storage products, architectural glass and other advanced applications.

Needham & Company acted as exclusive financial advisor to Advanced Energy Industries, Inc. in its acquisition of PV Powered, Inc. for a purchase price of up to $90 million consisting of $50 million to be paid at closing in the form of $35 million in cash and $15 million in Advanced Energy's common stock, as well as up to $40 million in a potential earn-out based on PV Powered's full year 2010 financial results. PV Powered Inc. is a leading manufacturer of grid-tied PV inverters in the residential, commercial, and utility-scale markets. Needham & Company provided a fairness opinion to Advanced Energy’s Board of Directors as part of its services. This acquisition will continue Advanced Energy’s strong momentum in the inverter market, propelling the company forward as a leading manufacturer of solar inverters in North America. As a combined company, the comprehensive portfolio of both transformerless and transformer-based inverter products will serve the entire spectrum of commercial project sizes from 30kw to multi-megawatt utility installations, placing Advanced Energy firmly at the heart of the emerging and fast-growing solar inverter market.

Microsemi Corporation (NASDAQ: MSCC) is a leading designer, manufacturer and marketer of high performance analog and mixed-signal integrated circuits, high reliability semiconductors and RF subsystems. The company's semiconductors manage and control or regulate power, protect against transient voltage spikes and transmit, receive and amplify signals. Microsemi's products include individual components as well as integrated circuit solutions that enhance customer designs by improving performance and reliability, battery optimization, reducing size or protecting circuits. The principal markets the company serves include implanted medical, defense/aerospace and satellite, notebook computers, monitors and LCD TVs, automotive and mobile connectivity applications. The company is headquartered in Irvine, California.

Needham & Company acted as financial advisor to Microsemi Corporation in its acquisition of White Electronic Designs Corporation (NASDAQ: WEDC), a leading designer, manufacturer and marketer of sophisticated multi-chip semiconductor packages, high-efficiency memory devices, and build-to-print electromechanical assemblies for defense and aerospace applications. This acquisition extends Microsemi’s offering into high-growth sectors in their core Aerospace & Defense markets and adds an extraordinary anti-tamper functionality to its existing product suite. Microsemi expects that there will be significant cost synergies from the transaction and that Microsemi can drive gross profit levels to its own corporate target as Microsemi exits lower margin business, drives a richer product mix, and realizes operational and other cost synergies by Microsemi's fourth fiscal quarter, ended October 3, 2010.

Seagate Technology (NASDAQ: STX) is the worldwide leader in the design, manufacture and marketing of hard disk drives and storage solutions, providing products for a wide-range of applications, including Enterprise, Desktop, Mobile Computing, Consumer Electronics and Branded Solutions. Seagate’s business model leverages technology leadership and world-class manufacturing to deliver industry-leading innovation and quality to its global customers, with the goal of being the time-to-market leader in all markets in which it participates. The company is committed to providing award-winning products, customer support and reliability to meet the world’s growing demand for information storage. Seagate can be found around the globe.

Seagate Technology (NASDAQ: STX) issued $600.0 million principal amount of 6.875 percent Senior Notes due 2020. The debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The underwriters fully exercised their option to purchase an additional $250 million principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction which priced in April 2010. In connection with the offering, Seagate terminated its $350 million senior secured corporate credit facility. The offering of the Notes and the termination of the Senior Credit Facility are part of Seagate’s efforts to optimize its sources of liquidity. Seagate Technology intends to use the remainder of the proceeds for general corporate purposes.

SPS Commerce, Inc. (NASDAQ: SPSC) is a leading provider of on-demand supply chain management solutions, providing integration, collaboration, connectivity, visibility and data analytics to thousands of customers worldwide. They deliver solutions over the Internet using a Software-as-a-Service model to improve the way suppliers, retailers, distributors and other customers manage and fulfill orders. The SPSCommerce.net platform features pre-built integrations used by current and new customers alike, spanning 2,700 order management models across 1,300 retailers, grocers and distributors, as well as integrations to over 100 accounting, warehouse management, enterprise resource planning, and packing and shipping applications. More than 35,000 customers across more than 40 countries have used SPSCommerce.net, making it one of the largest trading partner integration centers. SPS Commerce is headquartered in Minneapolis.

SPS Commerce, Inc. raised $56.5 million in its initial public offering at $12 per share. Needham acted as a Co-Lead Manager on the transaction.  The Company’s underwriters fully exercised their option to purchase an additional 614,504 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SPS Commerce, Inc. primarily to repay the indebtedness under equipment term loans that bear interest and mature in the year ending December 31, 2010, December 31, 2011 and January 1, 2012. The company intends to use the remaining net proceeds for working capital and other general corporate purposes, including potential acquisitions.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide is being evaluated as GATTEX in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and is in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceuticals.

NPS Pharmaceuticals, Inc. raised $56.9 million in a follow-on offering at $5.50 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,350,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by NPS Pharmaceuticals to fund clinical trials of their product candidates (GATTEX and NPSP558), to advance their preclinical research programs, and for working capital and other general corporate purposes.

EMC Corporation (NYSE: EMC) is the world's leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value from their information.

Needham & Company acted as financial advisor to EMC Corporation in its sale of certain Ionix assets to VMware, Inc. (NYSE: VMW) in an all cash transaction valued at approximately $200 million. Needham & Company provided a fairness opinion to EMC’s Board of Directors as part of its services. Under the terms of the agreement, VMware will acquire all technology and intellectual property of FastScale, Application Discovery Manager, Server Configuration Manager and Service Manager and will maintain engineering, marketing, sales and support operations in the United States, Europe, Israel, India and Australia. As part of the agreement, EMC will retain the Ionix brand and have full reseller rights to continue to offer customers the products acquired by VMware. This acquisition will complement existing VMware development efforts and expand the VMware vCenter product family with capabilities to meet stringent compliance standards in a dynamic virtualized environment. This new capability will provide a holistic view of configuration compliance of complete IT services from underlying physical assets to applications. VMware plans to further optimize the acquired products for dynamic, VMware vSphere-based cloud infrastructure, to deliver unparalleled visibility, control and simplicity of enterprise IT management. VMware, Inc. is the global leader in virtualization solutions from the desktop through the data center and to the cloud.

ViaSat, Inc. (NASDAQ: VSAT) produces innovative satellite and other digital communication products that enable fast, secure, and efficient communications to virtually any location. The company provides networking products and managed network services for enterprise IP applications; is a key supplier of network-centric military communications and encryption technologies and products to the U.S. government; is the primary technology partner for gateway and customer-premises equipment for consumer and mobile satellite broadband services; and owns WildBlue, the premier Ka-band satellite broadband service provider. ViaSat also offers design capabilities and a number of complementary products including monolithic microwave integrated circuits and modules, DVB-S2 satellite communication components, video data link systems, data acceleration and compression, and mobile satellite antenna systems. ViaSat is based in Carlsbad, CA. Major locations include Duluth, GA, Germantown, MD (Comsat Laboratories), and Greenwood Village, CO (WildBlue), along with additional field offices and service centers worldwide.

ViaSat, Inc. raised $231.2 million in a follow-on offering at $33.50 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 900,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by ViaSat for general corporate purposes, which may include working capital, capital expenditures, financing costs related to the purchase, launch and operation of its ViaSat-1 satellite or any future satellite, or other potential acquisitions. Pending application of the net proceeds as described above, ViaSat may use all or a portion of the net proceeds to repay outstanding borrowings under its revolving credit facility. ViaSat will not receive any proceeds from the sale of shares by the selling stockholders.

Dyax Corp. (NASDAQ: DYAX) is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. In December 2009 the FDA approved KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The Company started marketing KALBITOR in the U.S. with its own targeted sales force in February 2010. Dyax has ecallantide and other compounds in various stages for the clinical for multiple indications. Dyax is headquartered in Cambridge, Massachusetts.

Dyax raised $63.5 million in a follow-on offering at $3.25 per share. Needham & Company acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,550,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Dyax for to fund commercialization and distribution activities for KALBITOR to fund other research and preclinical development activities, and for general corporate purposes.

MaxLinear, Inc. (NYSE: MXL) is a provider of radio frequency (RF) and mixed-signal IC solutions for broadband communications applications. MaxLinear's high performance RF receiver products capture and process digital and analog broadband signals to be decoded for various applications. MaxLinear's current products enable the display of broadband video in a wide range of electronic devices, including cable and terrestrial set top boxes, digital televisions, mobile handsets, personal computers, netbooks, and in-vehicle entertainment devices. MaxLinear is based in Carlsbad, California.

MaxLinear, Inc. raised $103.7 million in its initial public offering at $14 per share (above its $11-$13 range).  Needham acted as a Co-Manager on the transaction.  The Company’s underwriters fully exercised their option to purchase an additional 996,614 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by MaxLinear, Inc. for general corporate purposes, including working capital. In addition, MaxLinear, Inc. also may use a portion of the net proceeds to acquire complementary businesses, products, services or technologies. The amount and timing of these expenditures will vary depending on a number of factors, including competitive and technological developments and the rate of growth, if any, of our business.

Netlist, Inc. (NASDAQ: NLST) designs and manufactures high-performance memory subsystems for the server and high- performance computing and communications markets. Netlist's memory subsystems are developed for applications in which high-speed, high-capacity memory, functionality, small form factor, and heat dissipation are key requirements. These applications include tower-servers, rack-mounted servers, blade servers, high-performance computing clusters, engineering workstations, and telecommunication equipment. Netlist maintains its headquarters in Irvine, California with manufacturing facilities in Suzhou, China.

Netlist, Inc. raised $17.7 million in a follow-on offering at $3.85 per share. Needham & Company acted as sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 599,250 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Netlist, Inc. to fund working capital and for other general corporate purposes.

Micromet, Inc. (NASDAQ: CHTP) is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials.  Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Micromet raised $80.5 million in a follow-on offering at $7 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,500,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Micromet, Inc. primarily for general corporate purposes, including clinical development of Blinatumomab in acute Lymphoblastic Leukemia and Non-Hodgkin´s Lymphoma as well as research and development, capital expenditures and working capital.

Teknovus is a leading developer and supplier of access chips and embedded software for the FTTx market, supporting EPON (Ethernet Passive Optical Networking) at 1G, 2.5G and 10G speeds. Teknovus products are deployed by more than 35 service providers around the world, enabling the delivery of advanced triple-play services, including IPTV, via optical fiber networks. Teknovus products support the full FTTx network, covering the Central Office (OLT) and the Customer Premises (ONU). Teknovus is headquartered in Petaluma, California with sales, design and support centers in Tokyo, Seoul, Beijing, Shanghai, Hong Kong, San Jose and Boston.

Needham & Company acted as exclusive financial advisor to Teknovus, Inc. in its sale to Broadcom Corporation (Nasdaq: BRCM) in an all cash transaction valued at approximately $123 million. Broadcom Corporation is a major technology innovator and global leader in semiconductors for wired and wireless communications. Broadcom® products enable the delivery of voice, video, data and multimedia to and throughout the home, the office and the mobile environment. The acquisition of Teknovus provides Broadcom with an established EPON technology. EPON represents approximately 94% of the FTTx connections in the Asia Pacific region and this acquisition allows Broadcom to enter the Asian broadband access market. EPON technology also complements Broadcom’s existing portfolio of switching, DSL, GPON, and cable solutions. As the EPON market segment evolves and expands, more technologies from both companies can be combined to enable a higher performance, lower cost EPON-based access infrastructure.

LTX-Credence Corporation (Nasdaq: LTXC) is a global provider of focused, cost-optimized ATE solutions designed to enable customers to implement best-in-class test strategies to maximize their profitability. LTX-Credence addresses the broad, divergent test requirements of the wireless, computing, automotive and entertainment market segments, offering a comprehensive portfolio of technologies, the largest installed base in the Asia-Pacific region, and a global network of strategically deployed applications and support resources.

LTX-Credence Corporation raised $50.8 million in a follow-on offering at $2.85 per share. Needham & Company, LLC acted as Joint-Lead Manager for this transaction. The underwriters fully exercised their option to purchase an additional 2,325,000 shares of common stock at the follow-on offering price to cover over-allotments. LTX-Credence intends to use these net proceeds for working capital and other general corporate purposes, including the possible reduction of indebtedness. This reduction of indebtedness may involve the repayment at maturity of the company's outstanding 3.50% convertible senior subordinated notes due 2010 and 2011; the repurchase of any such notes through open market repurchases, negotiated transactions or otherwise; or the repayment of all or a portion of the company's outstanding bank debt.

Chelsea Therapeutics (NASDAQ: CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of indications, including Droxidopa, an orally active synthetic precursor of norepinephrine, currently in a phase 3 clinical program, initially being developed for the treatment of neurogenic orthostatic hypotension, and CH-4051, a metabolically inert oral antifolate engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. 

Chelsea Therapeutics raised $18.2 million in a registered direct offering at $2.72 per Unit. Each Unit consists of one share of common stock and a warrant to purchase 0.35 of a share of common stock at an exercise price of $2.79 per share. The warrants have a 3-year term and are exercisable at any time after the 6-month anniversary of the date of issuance. The financing was led by funds affiliated with Venrock. Needham & Company acted as co-placement agent in the offering. The net proceeds from this transaction will be used by Chelsea to fund Chelsea’s droxidopa program, to fund Chalsea’s study of CH-4501 for the treatment of rheumatoid arthritis and to fund the development of other product candidates, including clinical trails, research and development expenses and general and administrative expenses, and for general corporate purposes.

PMFG, Inc. (Nasdaq: PMFG) is a leading provider of custom engineered systems and products designed to help ensure that the delivery of energy is safe, efficient and clean. The Company primarily serves the markets for power generation, natural gas infrastructure and petrochemical processing. Headquartered in Dallas, Texas, the Company markets its systems and products worldwide.

PMFG, Inc. raised $17.2 million in a follow-on offering at $11.50 per share. Needham & Company, LLC acted as Sole Manager for this transaction. Needham & Company fully exercised its option to purchase an additional 195,000 shares of common stock at the follow-on offering price to cover over-allotments. The Company intends to use 50% of the net proceeds from the offering to repay a portion of its outstanding borrowings under its senior term loan incurred in connection with the Company’s acquisition of Nitram Energy, Inc. in April 2008.  The balance of the net proceeds will be used for working capital and other general corporate purposes. Needham also served as the Sole Placement Agent on PMFG’s convertible preferred stock private placement of $21.1 million in September 2009.

Senomyx, Inc. (NASDAQ: SNMX) is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas.  The Company has product discovery and development collaborations with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx’s flavor ingredients. 

Senomyx, Inc. raised $20.0 million in a follow-on offering at $2.80 per share. Needham & Company acted as a co-manager on the transaction. The net proceeds from this transaction will be used by Senomyx to fund research and development efforts, and for general corporate purposes, including working capital.

Nova Measuring Instruments Ltd. (NASDAQ & TASE: NVMI) develops, produces and markets advanced integrated and stand alone metrology solutions for the semiconductor manufacturing industry.

Nova Measuring Instruments Ltd. raised $18.4 million in a follow-on offering at $4.15 per share. Needham & Company acted as sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 577,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Nova to fund working capital and for other general corporate purposes.

VaST Systems Technology Corporation is a leading provider in electronics virtualization. VaST fundamentally changes the electronics industry by breaking the dependency on hardware prototypes. With VaST, electronics companies develop virtual system prototypes-timing-accurate, high-speed simulation models of their electronic systems-for use in design and supply chain enablement. VaST's customers include worldwide leaders in automotive, consumer, and wireless markets.

Needham & Company acted as exclusive financial advisor to VaST Systems Technology Corporation in its sale to Synopsys, Inc. (Nasdaq: SNPS). The terms of the transaction are undisclosed. Synopsys, Inc. is a world leader in software and IP for semiconductor design, verification and manufacturing. This acquisition provides Synopsys, Inc. with the opportunity to extend its virtual prototyping solutions into the automotive and consumer application space. The acquisition adds a comprehensive set of processor sub-system models frequently found in automotive and consumer applications to Synopsys' virtual prototyping portfolio. Processor sub-system models allow developers to accelerate the virtualization of electronic systems and to start software development nine to 12 months prior to the availability of silicon.

California Micro Devices (was NASDAQ: CAMD) is a leading supplier of protection devices for the mobile handset, high brightness LED (HBLED), digital consumer electronics and personal computer markets.

Needham & Company acted as a financial advisor to California Micro Devices Corporation in its sale to ON Semiconductor (Nasdaq: ONNN) in an all cash transaction valued at approximately $107 million. Needham & Company provided a fairness opinion to CMD’s Board of Directors as part of its services. This acquisition will significantly strengthen ON Semiconductor’s offering of application specific integrated passive (ASIP) devices to protect products in the wireless, computing and consumer electronics end-markets. In addition, CMD’s expertise in protection solutions for the high brightness LED (HBLED) market, as well as their strengths in LC-based EMI (electromagnetic interference) filtering and low capacitance ESD (electrostatic discharge) protection, complement ON Semiconductor’s existing portfolio of protection and lighting solutions.

Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. Dendreon has its headquarters in Seattle, Washington.

Dendreon Corporation raised $426.9 million in a follow-on offering at $24.75 per share. Needham & Company acted as Co-Manager on the transaction. The Company’s underwriters fully exercised their option to purchase 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Dendreon to fund expenditures in connection with the investment in its manufacturing facilities, to fund investment in information technology infrastructure and product support systems, to hire manufacturing, sales and marketing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE® (sipuleucel-T), for third-party contract supply costs, and for general corporate purposes, including working capital.

Bankrate, Inc.'s businesses help consumers make informed decisions about their personal finance matters. The company's flagship brand, Bankrate.com is the leading aggregator of rates and other information on more than 300 financial products, including mortgages, credit cards, new and used auto loans, money market accounts and CDs, checking and ATM fees, home equity loans and online banking fees. 

Bankrate, Inc. has been acquired in a $571 million going-private transaction led by Apax Partners.  Needham & Company acted as financial advisor to the Independent Directors of Bankrate, Inc. and provided a fairness opinion as part of our services.

EMC Corporation (NYSE: EMC) completed its acquisition of Data Domain, Inc. (NASDAQ: DDUP). The transaction is valued at approximately $2.2 billion. Needham served as an advisor to EMC Corporation on the transaction. EMC Corporation is a leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value from their information.

Needham served as an advisor to EMC Corporation on the transaction.

Intel (NASDAQ: INTC) is the world leader in silicon innovation. The company develops technologies, products and initiatives to continually advance how people work and live.

Intel Corporation (NASDAQ: INTC) issued $2.00 billion principal amount of 3.25 percent junior subordinated convertible debentures due 2039. The debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, the underwriters also fully exercised their option to purchase $250 million principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction which priced in July 2009. Intel intends to use up to $1.5 billion of the net proceeds to purchase shares of its common stock concurrently with, or shortly after, pricing of the debentures from institutional investors in negotiated transactions through one or more of the initial purchasers, as Intel’s agent and under an accelerated stock repurchase program with one of the initial purchasers. Intel intends to use the remainder of the proceeds for general corporate purposes.

Motricity, Inc. (NASDAQ: MOTR) is a leading mobile data solutions provider exclusively focused on the rapidly growing mobile Internet market. It serves some of the world's largest mobile carriers, simplifying the mobile Internet and creating a personalized mobile experience for subscribers. Motricity helps companies leverage the power of mobility to make direct, personalized connections with their customers.

Motricity, Inc. raised $60.0 million in its initial public offering at $10 per share. Needham acted as a Co-Manager on the transaction. The net proceeds from the sale of the shares will be used by Motricity, Inc. primarily to fund investments in, and acquisitions of, competitive and complementary businesses, products or technologies, and other general corporate purposes.

BroadSoft, Inc. (NASDAQ: BSFT) is the leading global provider of software that enables fixed-line, mobile and cable service providers to deliver voice and multimedia services over their IP-based networks. The Company's software, BroadWorks®, enables its service provider customers to provide enterprises and consumers with a range of cloud-based, or hosted, IP multimedia communications, such as hosted IP private branch exchanges, video calling, unified communications, collaboration and converged mobile and fixed-line services.

BroadSoft, Inc. raised $67.5 million in its initial public offering at $9 per share. Needham acted as a Co-Manager on the transaction. The net proceeds from the sale of the shares will be used by BroadSoft, Inc. primarily to fund redemption and cancellation of preferred stock, repay existing debt, working capital, and other general corporate purposes.

MELA Sciences, Inc. (NASDAQ: MELA) is a medical technology company focused on developing MelaFind®, a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. MELA Sciences designed MelaFind® to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind® acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma. The MelaFind Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009 and is currently under review at the FDA. MELA Sciences cannot predict either the timing of the FDA's decision on the PMA application or the outcome. FDA approval is required prior to marketing MelaFind® in the United States. For more information on MELA Sciences, visit www.melasciences.com.

MELA Sciences, Inc. raised $16.5 million in a follow-on offering at $7.50 per share. Needham & Company acted as joint bookrunner on the transaction. The net proceeds from this transaction will be used by MELA Sciences, Inc. to fund the pursuit of its pre-market approval application (PMA) for MelaFind®, the continued development and, if and when approved by the U.S. Food and Drug Administration (FDA), the commercialization of MelaFind®, and for general corporate purposes, including working capital.

Sound Design Technologies, Ltd., an affiliate of Global Equity Capital, LLC is a leading designer and manufacturer of ultra-low-power semiconductor solutions for hearing aids and portable, battery-powered DSP applications, and a leading provider of advanced high density interconnect technologies used in custom miniaturized packages. Based in Burlington, Ontario, Canada, SDT has a 37-year history of innovation in developing miniaturized audio processors. The hearing instrument products and manufacturing operations of Gennum Corporation were acquired in 2007 to form SDT.

Needham & Company acted as financial advisor to Sound Design Technologies, Ltd. (STD) in its sale to ON Semiconductor Corporation (NASDAQ: ONNN) in an all cash transaction valued at approximately $32 million. This acquisition solidifies ON Semiconductor as a leading supplier of ultra-low-power digital signal processing (DSP) technology for hearing aids and audio processing applications. Matching SDT’s cutting-edge technology with ON Semiconductor’s worldwide presence and industry expertise is a natural next step in the evolution of the business, also benefiting SDT customers building sophisticated hearing products. ON Semiconductor Corporation is a premier supplier of high performance, energy efficient, silicon solutions for green electronics. Its broad portfolio of power and signal management, logic, discrete and custom devices helps customers efficiently solve their design challenges in automotive, communications, computing, consumer, industrial, LED lighting, medical, military/aerospace and power applications.

Heritage-Crystal Clean, Inc. (NASDAQ: HCCI) provides parts cleaning and hazardous and non-hazardous waste services to small and mid-sized customers in both the manufacturing and automotive service sectors. Their service programs include parts cleaning, containerized waste management, used oil collection, and vacuum truck services. These services help our customers manage their used chemicals and liquid and solid wastes, while also helping to minimize their regulatory burdens. Heritage-Crystal Clean’s customers include businesses involved in vehicle maintenance operations, such as car dealerships, automotive repair shops, and trucking firms, as well as small manufacturers, such as metal product fabricators and printers. The company is headquartered in Elgin, Illinois, and operates through 62 branches serving over 41,000 customer locations.

Heritage-Crystal Clean, Inc. raised $27.6 million in a follow-on offering at $8 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 450,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Heritage-Crystal Clean to fund a portion of the construction costs for the used oil re-refinery that it plans to build in Indiana.

Bottomline Technologies (NASDAQ: EPAY) is a leading provider of collaborative payment, invoice and document automation solutions to corporations, financial institutions and banks around the world. The company’s solutions are used to streamline, automate and manage processes involving payments, invoicing, global cash management, supply chain finance and transactional documents. Organizations trust these solutions to meet their needs for cost reduction, competitive differentiation and optimization of working capital. Headquartered in the United States, Bottomline also maintains offices in Europe and Asia-Pacific.

Bottomline Technologies raised $66.0 million in a follow-on offering at $14.50 per share. Needham & Company acted as sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 345,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Bottomline Technologies for general corporate purposes including acquisitions, working capital and capital expenditures.

ReachLocal, Inc.'s (NASDAQ: RLOC) mission is to help small- and medium-sized businesses acquire, maintain and retain customers via the Internet. ReachLocal offers a comprehensive suite of online marketing and reporting solutions, including search engine marketing, display advertising, remarketing and online marketing analytics, each targeted to the small- and medium-sized business market. ReachLocal delivers these solutions to small- and medium-sized businesses through a combination of its proprietary technology platform and its direct, "feet-on-the-street" sales force of Internet Marketing Consultants and select third party agencies and resellers. ReachLocal is headquartered in Woodland Hills, CA, with offices throughout North America and in Australia and the United Kingdom.

ReachLocal, Inc. raised $62.3 million in its initial public offering at $13 per share. Needham acted as a Co-Manager on the transaction.  The Company’s underwriters fully exercised their option to purchase an additional 625,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by ReachLocal, Inc. primarily for working capital and general corporate purposes. The Company will also use a portion of net proceeds of this offering to fulfill a deferred payment obligation of $6.1 million in connection with the acquisition in September 2009 of the approximately 53% of the Australian operations that the Company did not already own. The Company may use a portion of the net proceeds to acquire or invest in rights to complementary technologies, products, services or businesses.

Advanced Energy Industries, Inc. (NASDAQ: AEIS) is a global leader in innovative power and control technologies for high-growth, thin-film manufacturing and solar-power generation. Specifically, Advanced Energy targets solar grid-tie inverters, solar cells, semiconductors, flat panel displays, data storage products, architectural glass and other advanced applications.

Needham & Company acted as exclusive financial advisor to Advanced Energy Industries, Inc. in its acquisition of PV Powered, Inc. for a purchase price of up to $90 million consisting of $50 million to be paid at closing in the form of $35 million in cash and $15 million in Advanced Energy's common stock, as well as up to $40 million in a potential earn-out based on PV Powered's full year 2010 financial results. PV Powered Inc. is a leading manufacturer of grid-tied PV inverters in the residential, commercial, and utility-scale markets. Needham & Company provided a fairness opinion to Advanced Energy’s Board of Directors as part of its services. This acquisition will continue Advanced Energy’s strong momentum in the inverter market, propelling the company forward as a leading manufacturer of solar inverters in North America. As a combined company, the comprehensive portfolio of both transformerless and transformer-based inverter products will serve the entire spectrum of commercial project sizes from 30kw to multi-megawatt utility installations, placing Advanced Energy firmly at the heart of the emerging and fast-growing solar inverter market.

Microsemi Corporation (NASDAQ: MSCC) is a leading designer, manufacturer and marketer of high performance analog and mixed-signal integrated circuits, high reliability semiconductors and RF subsystems. The company's semiconductors manage and control or regulate power, protect against transient voltage spikes and transmit, receive and amplify signals. Microsemi's products include individual components as well as integrated circuit solutions that enhance customer designs by improving performance and reliability, battery optimization, reducing size or protecting circuits. The principal markets the company serves include implanted medical, defense/aerospace and satellite, notebook computers, monitors and LCD TVs, automotive and mobile connectivity applications. The company is headquartered in Irvine, California.

Needham & Company acted as financial advisor to Microsemi Corporation in its acquisition of White Electronic Designs Corporation (NASDAQ: WEDC), a leading designer, manufacturer and marketer of sophisticated multi-chip semiconductor packages, high-efficiency memory devices, and build-to-print electromechanical assemblies for defense and aerospace applications. This acquisition extends Microsemi’s offering into high-growth sectors in their core Aerospace & Defense markets and adds an extraordinary anti-tamper functionality to its existing product suite. Microsemi expects that there will be significant cost synergies from the transaction and that Microsemi can drive gross profit levels to its own corporate target as Microsemi exits lower margin business, drives a richer product mix, and realizes operational and other cost synergies by Microsemi's fourth fiscal quarter, ended October 3, 2010.

Seagate Technology (NASDAQ: STX) is the worldwide leader in the design, manufacture and marketing of hard disk drives and storage solutions, providing products for a wide-range of applications, including Enterprise, Desktop, Mobile Computing, Consumer Electronics and Branded Solutions. Seagate’s business model leverages technology leadership and world-class manufacturing to deliver industry-leading innovation and quality to its global customers, with the goal of being the time-to-market leader in all markets in which it participates. The company is committed to providing award-winning products, customer support and reliability to meet the world’s growing demand for information storage. Seagate can be found around the globe.

Seagate Technology (NASDAQ: STX) issued $600.0 million principal amount of 6.875 percent Senior Notes due 2020. The debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The underwriters fully exercised their option to purchase an additional $250 million principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction which priced in April 2010. In connection with the offering, Seagate terminated its $350 million senior secured corporate credit facility. The offering of the Notes and the termination of the Senior Credit Facility are part of Seagate’s efforts to optimize its sources of liquidity. Seagate Technology intends to use the remainder of the proceeds for general corporate purposes.

SPS Commerce, Inc. (NASDAQ: SPSC) is a leading provider of on-demand supply chain management solutions, providing integration, collaboration, connectivity, visibility and data analytics to thousands of customers worldwide. They deliver solutions over the Internet using a Software-as-a-Service model to improve the way suppliers, retailers, distributors and other customers manage and fulfill orders. The SPSCommerce.net platform features pre-built integrations used by current and new customers alike, spanning 2,700 order management models across 1,300 retailers, grocers and distributors, as well as integrations to over 100 accounting, warehouse management, enterprise resource planning, and packing and shipping applications. More than 35,000 customers across more than 40 countries have used SPSCommerce.net, making it one of the largest trading partner integration centers. SPS Commerce is headquartered in Minneapolis.

SPS Commerce, Inc. raised $56.5 million in its initial public offering at $12 per share. Needham acted as a Co-Lead Manager on the transaction.  The Company’s underwriters fully exercised their option to purchase an additional 614,504 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SPS Commerce, Inc. primarily to repay the indebtedness under equipment term loans that bear interest and mature in the year ending December 31, 2010, December 31, 2011 and January 1, 2012. The company intends to use the remaining net proceeds for working capital and other general corporate purposes, including potential acquisitions.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide is being evaluated as GATTEX in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and is in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceuticals.

NPS Pharmaceuticals, Inc. raised $56.9 million in a follow-on offering at $5.50 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,350,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by NPS Pharmaceuticals to fund clinical trials of their product candidates (GATTEX and NPSP558), to advance their preclinical research programs, and for working capital and other general corporate purposes.

EMC Corporation (NYSE: EMC) is the world's leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value from their information.

Needham & Company acted as financial advisor to EMC Corporation in its sale of certain Ionix assets to VMware, Inc. (NYSE: VMW) in an all cash transaction valued at approximately $200 million. Needham & Company provided a fairness opinion to EMC’s Board of Directors as part of its services. Under the terms of the agreement, VMware will acquire all technology and intellectual property of FastScale, Application Discovery Manager, Server Configuration Manager and Service Manager and will maintain engineering, marketing, sales and support operations in the United States, Europe, Israel, India and Australia. As part of the agreement, EMC will retain the Ionix brand and have full reseller rights to continue to offer customers the products acquired by VMware. This acquisition will complement existing VMware development efforts and expand the VMware vCenter product family with capabilities to meet stringent compliance standards in a dynamic virtualized environment. This new capability will provide a holistic view of configuration compliance of complete IT services from underlying physical assets to applications. VMware plans to further optimize the acquired products for dynamic, VMware vSphere-based cloud infrastructure, to deliver unparalleled visibility, control and simplicity of enterprise IT management. VMware, Inc. is the global leader in virtualization solutions from the desktop through the data center and to the cloud.

ViaSat, Inc. (NASDAQ: VSAT) produces innovative satellite and other digital communication products that enable fast, secure, and efficient communications to virtually any location. The company provides networking products and managed network services for enterprise IP applications; is a key supplier of network-centric military communications and encryption technologies and products to the U.S. government; is the primary technology partner for gateway and customer-premises equipment for consumer and mobile satellite broadband services; and owns WildBlue, the premier Ka-band satellite broadband service provider. ViaSat also offers design capabilities and a number of complementary products including monolithic microwave integrated circuits and modules, DVB-S2 satellite communication components, video data link systems, data acceleration and compression, and mobile satellite antenna systems. ViaSat is based in Carlsbad, CA. Major locations include Duluth, GA, Germantown, MD (Comsat Laboratories), and Greenwood Village, CO (WildBlue), along with additional field offices and service centers worldwide.

ViaSat, Inc. raised $231.2 million in a follow-on offering at $33.50 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 900,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by ViaSat for general corporate purposes, which may include working capital, capital expenditures, financing costs related to the purchase, launch and operation of its ViaSat-1 satellite or any future satellite, or other potential acquisitions. Pending application of the net proceeds as described above, ViaSat may use all or a portion of the net proceeds to repay outstanding borrowings under its revolving credit facility. ViaSat will not receive any proceeds from the sale of shares by the selling stockholders.

Dyax Corp. (NASDAQ: DYAX) is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. In December 2009 the FDA approved KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The Company started marketing KALBITOR in the U.S. with its own targeted sales force in February 2010. Dyax has ecallantide and other compounds in various stages for the clinical for multiple indications. Dyax is headquartered in Cambridge, Massachusetts.

Dyax raised $63.5 million in a follow-on offering at $3.25 per share. Needham & Company acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,550,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Dyax for to fund commercialization and distribution activities for KALBITOR to fund other research and preclinical development activities, and for general corporate purposes.

MaxLinear, Inc. (NYSE: MXL) is a provider of radio frequency (RF) and mixed-signal IC solutions for broadband communications applications. MaxLinear's high performance RF receiver products capture and process digital and analog broadband signals to be decoded for various applications. MaxLinear's current products enable the display of broadband video in a wide range of electronic devices, including cable and terrestrial set top boxes, digital televisions, mobile handsets, personal computers, netbooks, and in-vehicle entertainment devices. MaxLinear is based in Carlsbad, California.

MaxLinear, Inc. raised $103.7 million in its initial public offering at $14 per share (above its $11-$13 range).  Needham acted as a Co-Manager on the transaction.  The Company’s underwriters fully exercised their option to purchase an additional 996,614 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by MaxLinear, Inc. for general corporate purposes, including working capital. In addition, MaxLinear, Inc. also may use a portion of the net proceeds to acquire complementary businesses, products, services or technologies. The amount and timing of these expenditures will vary depending on a number of factors, including competitive and technological developments and the rate of growth, if any, of our business.

Netlist, Inc. (NASDAQ: NLST) designs and manufactures high-performance memory subsystems for the server and high- performance computing and communications markets. Netlist's memory subsystems are developed for applications in which high-speed, high-capacity memory, functionality, small form factor, and heat dissipation are key requirements. These applications include tower-servers, rack-mounted servers, blade servers, high-performance computing clusters, engineering workstations, and telecommunication equipment. Netlist maintains its headquarters in Irvine, California with manufacturing facilities in Suzhou, China.

Netlist, Inc. raised $17.7 million in a follow-on offering at $3.85 per share. Needham & Company acted as sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 599,250 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Netlist, Inc. to fund working capital and for other general corporate purposes.

Micromet, Inc. (NASDAQ: CHTP) is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials.  Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Micromet raised $80.5 million in a follow-on offering at $7 per share. Needham & Company acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,500,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Micromet, Inc. primarily for general corporate purposes, including clinical development of Blinatumomab in acute Lymphoblastic Leukemia and Non-Hodgkin´s Lymphoma as well as research and development, capital expenditures and working capital.

Teknovus is a leading developer and supplier of access chips and embedded software for the FTTx market, supporting EPON (Ethernet Passive Optical Networking) at 1G, 2.5G and 10G speeds. Teknovus products are deployed by more than 35 service providers around the world, enabling the delivery of advanced triple-play services, including IPTV, via optical fiber networks. Teknovus products support the full FTTx network, covering the Central Office (OLT) and the Customer Premises (ONU). Teknovus is headquartered in Petaluma, California with sales, design and support centers in Tokyo, Seoul, Beijing, Shanghai, Hong Kong, San Jose and Boston.

Needham & Company acted as exclusive financial advisor to Teknovus, Inc. in its sale to Broadcom Corporation (Nasdaq: BRCM) in an all cash transaction valued at approximately $123 million. Broadcom Corporation is a major technology innovator and global leader in semiconductors for wired and wireless communications. Broadcom® products enable the delivery of voice, video, data and multimedia to and throughout the home, the office and the mobile environment. The acquisition of Teknovus provides Broadcom with an established EPON technology. EPON represents approximately 94% of the FTTx connections in the Asia Pacific region and this acquisition allows Broadcom to enter the Asian broadband access market. EPON technology also complements Broadcom’s existing portfolio of switching, DSL, GPON, and cable solutions. As the EPON market segment evolves and expands, more technologies from both companies can be combined to enable a higher performance, lower cost EPON-based access infrastructure.

LTX-Credence Corporation (Nasdaq: LTXC) is a global provider of focused, cost-optimized ATE solutions designed to enable customers to implement best-in-class test strategies to maximize their profitability. LTX-Credence addresses the broad, divergent test requirements of the wireless, computing, automotive and entertainment market segments, offering a comprehensive portfolio of technologies, the largest installed base in the Asia-Pacific region, and a global network of strategically deployed applications and support resources.

LTX-Credence Corporation raised $50.8 million in a follow-on offering at $2.85 per share. Needham & Company, LLC acted as Joint-Lead Manager for this transaction. The underwriters fully exercised their option to purchase an additional 2,325,000 shares of common stock at the follow-on offering price to cover over-allotments. LTX-Credence intends to use these net proceeds for working capital and other general corporate purposes, including the possible reduction of indebtedness. This reduction of indebtedness may involve the repayment at maturity of the company's outstanding 3.50% convertible senior subordinated notes due 2010 and 2011; the repurchase of any such notes through open market repurchases, negotiated transactions or otherwise; or the repayment of all or a portion of the company's outstanding bank debt.

Chelsea Therapeutics (NASDAQ: CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of indications, including Droxidopa, an orally active synthetic precursor of norepinephrine, currently in a phase 3 clinical program, initially being developed for the treatment of neurogenic orthostatic hypotension, and CH-4051, a metabolically inert oral antifolate engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. 

Chelsea Therapeutics raised $18.2 million in a registered direct offering at $2.72 per Unit. Each Unit consists of one share of common stock and a warrant to purchase 0.35 of a share of common stock at an exercise price of $2.79 per share. The warrants have a 3-year term and are exercisable at any time after the 6-month anniversary of the date of issuance. The financing was led by funds affiliated with Venrock. Needham & Company acted as co-placement agent in the offering. The net proceeds from this transaction will be used by Chelsea to fund Chelsea’s droxidopa program, to fund Chalsea’s study of CH-4501 for the treatment of rheumatoid arthritis and to fund the development of other product candidates, including clinical trails, research and development expenses and general and administrative expenses, and for general corporate purposes.

PMFG, Inc. (Nasdaq: PMFG) is a leading provider of custom engineered systems and products designed to help ensure that the delivery of energy is safe, efficient and clean. The Company primarily serves the markets for power generation, natural gas infrastructure and petrochemical processing. Headquartered in Dallas, Texas, the Company markets its systems and products worldwide.

PMFG, Inc. raised $17.2 million in a follow-on offering at $11.50 per share. Needham & Company, LLC acted as Sole Manager for this transaction. Needham & Company fully exercised its option to purchase an additional 195,000 shares of common stock at the follow-on offering price to cover over-allotments. The Company intends to use 50% of the net proceeds from the offering to repay a portion of its outstanding borrowings under its senior term loan incurred in connection with the Company’s acquisition of Nitram Energy, Inc. in April 2008.  The balance of the net proceeds will be used for working capital and other general corporate purposes. Needham also served as the Sole Placement Agent on PMFG’s convertible preferred stock private placement of $21.1 million in September 2009.

Senomyx, Inc. (NASDAQ: SNMX) is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas.  The Company has product discovery and development collaborations with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx’s flavor ingredients. 

Senomyx, Inc. raised $20.0 million in a follow-on offering at $2.80 per share. Needham & Company acted as a co-manager on the transaction. The net proceeds from this transaction will be used by Senomyx to fund research and development efforts, and for general corporate purposes, including working capital.

Nova Measuring Instruments Ltd. (NASDAQ & TASE: NVMI) develops, produces and markets advanced integrated and stand alone metrology solutions for the semiconductor manufacturing industry.

Nova Measuring Instruments Ltd. raised $18.4 million in a follow-on offering at $4.15 per share. Needham & Company acted as sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 577,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Nova to fund working capital and for other general corporate purposes.

VaST Systems Technology Corporation is a leading provider in electronics virtualization. VaST fundamentally changes the electronics industry by breaking the dependency on hardware prototypes. With VaST, electronics companies develop virtual system prototypes-timing-accurate, high-speed simulation models of their electronic systems-for use in design and supply chain enablement. VaST's customers include worldwide leaders in automotive, consumer, and wireless markets.

Needham & Company acted as exclusive financial advisor to VaST Systems Technology Corporation in its sale to Synopsys, Inc. (Nasdaq: SNPS). The terms of the transaction are undisclosed. Synopsys, Inc. is a world leader in software and IP for semiconductor design, verification and manufacturing. This acquisition provides Synopsys, Inc. with the opportunity to extend its virtual prototyping solutions into the automotive and consumer application space. The acquisition adds a comprehensive set of processor sub-system models frequently found in automotive and consumer applications to Synopsys' virtual prototyping portfolio. Processor sub-system models allow developers to accelerate the virtualization of electronic systems and to start software development nine to 12 months prior to the availability of silicon.

California Micro Devices (was NASDAQ: CAMD) is a leading supplier of protection devices for the mobile handset, high brightness LED (HBLED), digital consumer electronics and personal computer markets.

Needham & Company acted as a financial advisor to California Micro Devices Corporation in its sale to ON Semiconductor (Nasdaq: ONNN) in an all cash transaction valued at approximately $107 million. Needham & Company provided a fairness opinion to CMD’s Board of Directors as part of its services. This acquisition will significantly strengthen ON Semiconductor’s offering of application specific integrated passive (ASIP) devices to protect products in the wireless, computing and consumer electronics end-markets. In addition, CMD’s expertise in protection solutions for the high brightness LED (HBLED) market, as well as their strengths in LC-based EMI (electromagnetic interference) filtering and low capacitance ESD (electrostatic discharge) protection, complement ON Semiconductor’s existing portfolio of protection and lighting solutions.

Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. Dendreon has its headquarters in Seattle, Washington.

Dendreon Corporation raised $426.9 million in a follow-on offering at $24.75 per share. Needham & Company acted as Co-Manager on the transaction. The Company’s underwriters fully exercised their option to purchase 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from this transaction will be used by Dendreon to fund expenditures in connection with the investment in its manufacturing facilities, to fund investment in information technology infrastructure and product support systems, to hire manufacturing, sales and marketing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE® (sipuleucel-T), for third-party contract supply costs, and for general corporate purposes, including working capital.

Bankrate, Inc.'s businesses help consumers make informed decisions about their personal finance matters. The company's flagship brand, Bankrate.com is the leading aggregator of rates and other information on more than 300 financial products, including mortgages, credit cards, new and used auto loans, money market accounts and CDs, checking and ATM fees, home equity loans and online banking fees. 

Bankrate, Inc. has been acquired in a $571 million going-private transaction led by Apax Partners.  Needham & Company acted as financial advisor to the Independent Directors of Bankrate, Inc. and provided a fairness opinion as part of our services.

EMC Corporation (NYSE: EMC) completed its acquisition of Data Domain, Inc. (NASDAQ: DDUP). The transaction is valued at approximately $2.2 billion. Needham served as an advisor to EMC Corporation on the transaction. EMC Corporation is a leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value from their information.

Needham served as an advisor to EMC Corporation on the transaction.

Intel (NASDAQ: INTC) is the world leader in silicon innovation. The company develops technologies, products and initiatives to continually advance how people work and live.

Intel Corporation (NASDAQ: INTC) issued $2.00 billion principal amount of 3.25 percent junior subordinated convertible debentures due 2039. The debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, the underwriters also fully exercised their option to purchase $250 million principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction which priced in July 2009. Intel intends to use up to $1.5 billion of the net proceeds to purchase shares of its common stock concurrently with, or shortly after, pricing of the debentures from institutional investors in negotiated transactions through one or more of the initial purchasers, as Intel’s agent and under an accelerated stock repurchase program with one of the initial purchasers. Intel intends to use the remainder of the proceeds for general corporate purposes.